// App-Quantinova.ai

: Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to assess the value of abiraterone acetate (AA) and enzalutamide (E) in advanced prostate cancer: clinical value and cost considerations.

Researchers

Presenter

  • Sarah Wong

Principal Investigators

  • Louis Everest

  • Di Maria Jiang

  • Ronak Saluja

  • Kelvin K. Chan

  • Srikala S. Sridhar

Medical Centers

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Sunnybrook Health Sciences Centre, Odette Cancer Centre, University of Toronto, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Enzalutamide

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved